Evaluation of suPAR levels in patients with COVID-19 and non-COVID-19 Pneumonia: An observational cohort study
Thu Oct 14 2021
Evaluation of suPAR levels in patients with COVID-19 and non-COVID-19 Pneumonia: An observational cohort study
Results
In patients hospitalized with chest infections, COVID-19 patients showed significantly higher suPAR levels upon admission compared to those without COVID-19. suPAR proved to be a powerful predictor of in-hospital mortality in the COVID-19 group.
Conclusions
Measuring suPAR at admission can offer vital prognostic insights for suspected COVID-19 pneumonia cases. suPAR levels were notably higher in patients testing positive for SARS-CoV-2 via real-time PCR, demonstrating outstanding prognostic value for predicting in-hospital mortality.
suPAR, an inflammatory biomarker, is easy to measure in clinical settings, including emergency departments. It allows for rapid, on-site results (within 20 minutes), facilitating immediate clinical decision-making even before hospital admission.
Background
SARS-CoV-2 primarily affects the respiratory system, leading to hospitalization for many. suPAR, indicative of both acute and chronic inflammation, has been recognized for its strong predictive value for mortality in COVID-19 cases. This study aimed to assess suPAR’s effectiveness compared to other lab biomarkers in patients with suspected COVID-19 pneumonia.
Methods
The study included 41 patients with chest infections, divided into two groups based on their SARS-CoV-2 PCR test results. Both groups were comparable in terms of age, sex, PO2/FiO2 ratio, and mortality rates.
